Presenting results at ASCO does not guarantee brilliant results yet, but it does show that the findings are worthy of ASCO, which is a truly massive and significant event in oncology.
Orion has already stated that ODM-212 showed clinical activity and tolerable safety in Phase 1, which is further evidenced by the fact that Phase 2 has already been underway since the beginning of the year. https://www.orionpharma.com/fi/uutishuone/kaikki-uutiset/tiedotteet/lehdistotiedotteet/2026/orion-pharma-on-aloittanut-odm-212-molekyylilla-teades-faasi-2–tutkimuksen-pahanlaatuisen-keuhkopussin-mesoteliooman-mpm-ja-epitelioidi-hemangioendoteliooman-ehe-hoidossa/ Now we will hear more detailed information regarding Phase 1.
Orphan drug status has already been granted for pleural cancer. Additionally, it is being studied for rare sarcoma—diseases where the “hippo pathway” (hipporeitti) is active.
Let’s hope this molecule turns out to be a “hippo-sized” revelation. If Phase 2 is also successful, I expect the same licensing strategy will be pursued as with darolutamide, aka Nubeqa. There is competition on that pathway, which speaks to its significance, but it also adds business risk: if it works, who does it best, and who gets the biggest piece of the cake? They are starting with “rare cakes,” but there is potential for several cancer types where this signaling pathway is utilized by the cancer. The abstracts should become public today at midnight Finnish time.